Cost-effectiveness of repeated interventions on failing arteriovenous fistulas. Brooke, B. S., Griffin, C. L., Kraiss, L. W., Kim, J., & Nelson, R. Journal of Vascular Surgery, 70(5):1620–1628, November, 2019.
Cost-effectiveness of repeated interventions on failing arteriovenous fistulas [link]Paper  doi  abstract   bibtex   
Objective: Arteriovenous fistulas (AVFs) used for hemodialysis commonly undergo multiple percutaneous and open interventions to maintain functional patency, but it is unclear whether this strategy is cost-effective. The aim of this study was to evaluate the clinical effectiveness and cost-effectiveness of performing repeated interventions vs starting a new AVF. Methods: We reviewed all patients with mature radiocephalic, brachiocephalic, and brachiobasilic AVFs at a single academic institution between 2007 and 2015 and assessed the clinical effectiveness of each open and percutaneous intervention to maintain functional patency after the fistula was created. These data were used to parameterize a Markov simulation model to determine the cost-effectiveness for performing an open or percutaneous intervention vs creating an AVF at a new anatomic location. This model compared strategies of creating a new AVF after the first to fourth reintervention within a 1-year time window, with the reference being creation of a new AVF on the fourth reintervention. Costs were measured from Medicare’s perspective, and effectiveness was measured as quality-adjusted life-years (QALYs) and time in functional access. Incremental cost-effectiveness ratios (ICERs) were calculated by taking the ratio of the difference in cost and the difference in effectiveness between two strategies. Results: A total of 720 AVFs that were created during the 8-year period reached maturity, and 407 (56%) underwent at least one intervention to maintain functional patency, with the median (interquartile range) time to first reintervention of 12.6 (10-17) months. For the strategies of creating a new AVF after the first versus the fourth reintervention, payer costs ranged from $3519 to $3922 for open procedures and $2134 to $3922 for percutaneous procedures. The ICERs for open interventions on failing AVFs were $357,143/QALY after the first reintervention and $95,876/QALY after the second reintervention. The ICERs for percutaneous interventions on failing AVFs ranged from $1,522,078/QALY after the first reintervention to $443,243/QALY after the third reintervention. Conclusions: Whereas the clinical effectiveness of performing percutaneous interventions on failing AVFs diminishes after each reintervention, they are nevertheless less costly than creating a new AVF. In comparison, our data show that creating a new AVF is cost-effective after the second open reintervention procedure. (J Vasc Surg 2019;70:1620-8.)
@article{brooke_cost-effectiveness_2019-3,
	title = {Cost-effectiveness of repeated interventions on failing arteriovenous fistulas},
	volume = {70},
	issn = {07415214},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S0741521419303751},
	doi = {10.1016/j.jvs.2019.01.085},
	abstract = {Objective: Arteriovenous fistulas (AVFs) used for hemodialysis commonly undergo multiple percutaneous and open interventions to maintain functional patency, but it is unclear whether this strategy is cost-effective. The aim of this study was to evaluate the clinical effectiveness and cost-effectiveness of performing repeated interventions vs starting a new AVF. Methods: We reviewed all patients with mature radiocephalic, brachiocephalic, and brachiobasilic AVFs at a single academic institution between 2007 and 2015 and assessed the clinical effectiveness of each open and percutaneous intervention to maintain functional patency after the fistula was created. These data were used to parameterize a Markov simulation model to determine the cost-effectiveness for performing an open or percutaneous intervention vs creating an AVF at a new anatomic location. This model compared strategies of creating a new AVF after the first to fourth reintervention within a 1-year time window, with the reference being creation of a new AVF on the fourth reintervention. Costs were measured from Medicare’s perspective, and effectiveness was measured as quality-adjusted life-years (QALYs) and time in functional access. Incremental cost-effectiveness ratios (ICERs) were calculated by taking the ratio of the difference in cost and the difference in effectiveness between two strategies. Results: A total of 720 AVFs that were created during the 8-year period reached maturity, and 407 (56\%) underwent at least one intervention to maintain functional patency, with the median (interquartile range) time to first reintervention of 12.6 (10-17) months. For the strategies of creating a new AVF after the first versus the fourth reintervention, payer costs ranged from \$3519 to \$3922 for open procedures and \$2134 to \$3922 for percutaneous procedures. The ICERs for open interventions on failing AVFs were \$357,143/QALY after the first reintervention and \$95,876/QALY after the second reintervention. The ICERs for percutaneous interventions on failing AVFs ranged from \$1,522,078/QALY after the first reintervention to \$443,243/QALY after the third reintervention. Conclusions: Whereas the clinical effectiveness of performing percutaneous interventions on failing AVFs diminishes after each reintervention, they are nevertheless less costly than creating a new AVF. In comparison, our data show that creating a new AVF is cost-effective after the second open reintervention procedure. (J Vasc Surg 2019;70:1620-8.)},
	language = {en},
	number = {5},
	urldate = {2022-04-04},
	journal = {Journal of Vascular Surgery},
	author = {Brooke, Benjamin S. and Griffin, Claire L. and Kraiss, Larry W. and Kim, Jaewhan and Nelson, Richard},
	month = nov,
	year = {2019},
	pages = {1620--1628},
	file = {98b960173c141fe0.pdf:/Users/neil.hawkins/Zotero/storage/3CLI7R2D/98b960173c141fe0.pdf:application/pdf;178.full.pdf:/Users/neil.hawkins/Zotero/storage/INAHYPPT/178.full.pdf:application/pdf;0272989x15605094.pdf:/Users/neil.hawkins/Zotero/storage/A3RSIELZ/0272989x15605094.pdf:application/pdf;Brazier2009_Article_TheRoleOfPatientPreferencesInC.pdf:/Users/neil.hawkins/Zotero/storage/MEYWZI9Z/Brazier2009_Article_TheRoleOfPatientPreferencesInC.pdf:application/pdf;Brooke et al. - 2019 - Cost-effectiveness of repeated interventions on fa.pdf:/Users/neil.hawkins/Zotero/storage/428UIY8S/Brooke et al. - 2019 - Cost-effectiveness of repeated interventions on fa.pdf:application/pdf;Devlin2019_Article_ANewMethodForValuingHealthDire.pdf:/Users/neil.hawkins/Zotero/storage/5GLE8VV9/Devlin2019_Article_ANewMethodForValuingHealthDire.pdf:application/pdf;Giannini2021_Article_BurdenOfDiseaseAndClinicalTarg.pdf:/Users/neil.hawkins/Zotero/storage/Q57I2JXX/Giannini2021_Article_BurdenOfDiseaseAndClinicalTarg.pdf:application/pdf;Gibbs.pdf:/Users/neil.hawkins/Zotero/storage/DVKBZESY/Gibbs.pdf:application/pdf;GOe_FP_AMR_Report_final.pdf:/Users/neil.hawkins/Zotero/storage/3FE8Q6RW/GOe_FP_AMR_Report_final.pdf:application/pdf;gp_overview_guide.pdf:/Users/neil.hawkins/Zotero/storage/3DBRTUHF/gp_overview_guide.pdf:application/pdf;gray_supplementary.docx:/Users/neil.hawkins/Zotero/storage/LQHWMTDV/gray_supplementary.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;gray_viH (1).pdf:/Users/neil.hawkins/Zotero/storage/4LAMER9V/gray_viH (1).pdf:application/pdf;Gries2017_Article_UtilityEstimatesOfDisease-Spec.pdf:/Users/neil.hawkins/Zotero/storage/ZB8A8MDV/Gries2017_Article_UtilityEstimatesOfDisease-Spec.pdf:application/pdf;Grimm2021_Article_MogamulizumabForPreviouslyTrea.pdf:/Users/neil.hawkins/Zotero/storage/TGTK354L/Grimm2021_Article_MogamulizumabForPreviouslyTrea.pdf:application/pdf;Guidance-on-choosing-qualitative-evidence-synthesis-methods-for-use-in-HTA-of-complex-interventions.pdf:/Users/neil.hawkins/Zotero/storage/7HWNX227/Guidance-on-choosing-qualitative-evidence-synthesis-methods-for-use-in-HTA-of-complex-interventions.pdf:application/pdf;Guidance-on-the-use-of-logic-models-in-health-technology-assessments-of-complex-interventions.pdf:/Users/neil.hawkins/Zotero/storage/TRK5FY23/Guidance-on-the-use-of-logic-models-in-health-technology-assessments-of-complex-interventions.pdf:application/pdf;guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.pdf:/Users/neil.hawkins/Zotero/storage/SJAC9ACN/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.pdf:application/pdf;hamerle2.pdf:/Users/neil.hawkins/Zotero/storage/B9JZ7BB6/hamerle2.pdf:application/pdf;hanley_mcneil_radiology_82.pdf:/Users/neil.hawkins/Zotero/storage/9A8GJ3MB/hanley_mcneil_radiology_82.pdf:application/pdf;Hansen2019_Article_PostponementOfDeathByStatinUse.pdf:/Users/neil.hawkins/Zotero/storage/L5KDKIH6/Hansen2019_Article_PostponementOfDeathByStatinUse.pdf:application/pdf;Hawley S et al Comorbidities in XLH Rheumatology 2020.pdf:/Users/neil.hawkins/Zotero/storage/BM63NTZD/Hawley S et al Comorbidities in XLH Rheumatology 2020.pdf:application/pdf;Health Economics - 2011 - Hawkins - Surrogates  meta‐analysis and cost‐effectiveness modelling  a combined analytic.pdf:/Users/neil.hawkins/Zotero/storage/9IQ33QXL/Health Economics - 2011 - Hawkins - Surrogates  meta‐analysis and cost‐effectiveness modelling  a combined analytic.pdf:application/pdf;Health Economics - 2019 - Megiddo - Investing in antibiotics to alleviate future catastrophic outcomes  What is the value (2).pdf:/Users/neil.hawkins/Zotero/storage/HV8MFC62/Health Economics - 2019 - Megiddo - Investing in antibiotics to alleviate future catastrophic outcomes  What is the value (2).pdf:application/pdf;Health Economics - 2021 - Woods - Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers.pdf:/Users/neil.hawkins/Zotero/storage/KNV8GJ9R/Health Economics - 2021 - Woods - Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers.pdf:application/pdf;Health technology assessment HTA and economic evaluation efficiency or fairness first.pdf:/Users/neil.hawkins/Zotero/storage/WIXG26NT/Health technology assessment HTA and economic evaluation efficiency or fairness first.pdf:application/pdf;Health technology assessment in Japan a work in progress.pdf:/Users/neil.hawkins/Zotero/storage/8ML5NJ5A/Health technology assessment in Japan a work in progress.pdf:application/pdf;Health utilities in relation to treatment response and adverse events in relapsed refractory Hodgkin lymphoma and systemic anaplastic large cell.pdf:/Users/neil.hawkins/Zotero/storage/VZFQPB4T/Health utilities in relation to treatment response and adverse events in relapsed refractory Hodgkin lymphoma and systemic anaplastic large cell.pdf:application/pdf;Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit_a systematic review_Villeneuve_IntenCareMed_2016.pdf:/Users/neil.hawkins/Zotero/storage/BQ6ZCSRU/Health-related quality-of-life among survivors of acute kidney injury in the intensive care unit_a systematic review_Villeneuve_IntenCareMed_2016.pdf:application/pdf;Health-Technology-Assessment-for-the-U.S.-Healthcare-System_Background-Paper.pdf:/Users/neil.hawkins/Zotero/storage/VA8ILE9V/Health-Technology-Assessment-for-the-U.S.-Healthcare-System_Background-Paper.pdf:application/pdf;HEC-20-0653_Proof_hi.pdf:/Users/neil.hawkins/Zotero/storage/HR2IDXCN/HEC-20-0653_Proof_hi.pdf:application/pdf;hec.3021.pdf:/Users/neil.hawkins/Zotero/storage/5RHE7E54/hec.3021.pdf:application/pdf;Heerspink - DAPA-CKD Primary Pub - NEJM 2020.pdf:/Users/neil.hawkins/Zotero/storage/EWJHLSZN/Heerspink - DAPA-CKD Primary Pub - NEJM 2020.pdf:application/pdf;Henderson_2016.pdf:/Users/neil.hawkins/Zotero/storage/EMIBR79A/Henderson_2016.pdf:application/pdf;hlthaff.2014.1003 (1).pdf:/Users/neil.hawkins/Zotero/storage/QZXFFHW3/hlthaff.2014.1003 (1).pdf:application/pdf;hlthaff.2014.1003.pdf:/Users/neil.hawkins/Zotero/storage/8AYLSKRC/hlthaff.2014.1003.pdf:application/pdf;Hoyle2008.pdf:/Users/neil.hawkins/Zotero/storage/RA7N7PDB/Hoyle2008.pdf:application/pdf;HST-batch-34-block-scoping-report.pdf:/Users/neil.hawkins/Zotero/storage/NKLX3YZA/HST-batch-34-block-scoping-report.pdf:application/pdf;HST-batch-36-block-scoping-report.pdf:/Users/neil.hawkins/Zotero/storage/CT2FGWHA/HST-batch-36-block-scoping-report.pdf:application/pdf;hst-batch-37b-block-scoping-report.pdf:/Users/neil.hawkins/Zotero/storage/EXVDDJHU/hst-batch-37b-block-scoping-report.pdf:application/pdf;hst-batch-40-block-scoping-report.pdf:/Users/neil.hawkins/Zotero/storage/48L4PXB6/hst-batch-40-block-scoping-report.pdf:application/pdf;HST-batch-55-block-scoping-report.pdf:/Users/neil.hawkins/Zotero/storage/MDRMYA9L/HST-batch-55-block-scoping-report.pdf:application/pdf;HST-interim-methods-process-guide-may-17.pdf:/Users/neil.hawkins/Zotero/storage/YNHJWR3U/HST-interim-methods-process-guide-may-17.pdf:application/pdf;HTA Report SG Analysis_2001.pdf:/Users/neil.hawkins/Zotero/storage/HAFX2G57/HTA Report SG Analysis_2001.pdf:application/pdf;ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf:/Users/neil.hawkins/Zotero/storage/NEGB4TX7/ich-e-9-statistical-principles-clinical-trials-step-5_en.pdf:application/pdf;ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf:/Users/neil.hawkins/Zotero/storage/Z7UDCHI9/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf:application/pdf;ICNMD-Program.pdf:/Users/neil.hawkins/Zotero/storage/243B3DFL/ICNMD-Program.pdf:application/pdf;INCISE_Transcriptomics_Review.pdf:/Users/neil.hawkins/Zotero/storage/NFUNJXDX/INCISE_Transcriptomics_Review.pdf:application/pdf;integrating-early-economic-evaluation-into-target-product-profile-development-for-medical-tests-advantages-and-potential-applications.pdf:/Users/neil.hawkins/Zotero/storage/AT968JQ5/integrating-early-economic-evaluation-into-target-product-profile-development-for-medical-tests-advantages-and-potential-applications.pdf:application/pdf;invitation-to-submit-final-tender.pdf:/Users/neil.hawkins/Zotero/storage/EILFQPEV/invitation-to-submit-final-tender.pdf:application/pdf;iRECORD AGM_WP3 meeting slides.pdf:/Users/neil.hawkins/Zotero/storage/ULG9MI4K/iRECORD AGM_WP3 meeting slides.pdf:application/pdf;j.1365-2133.2005.06893.x (1).pdf:/Users/neil.hawkins/Zotero/storage/T7NEAJ39/j.1365-2133.2005.06893.x (1).pdf:application/pdf;jama_277_1_034.pdf:/Users/neil.hawkins/Zotero/storage/DZZJV7ME/jama_277_1_034.pdf:application/pdf;jama_darrow_2020_sc_190008.pdf:/Users/neil.hawkins/Zotero/storage/6FTXMTLS/jama_darrow_2020_sc_190008.pdf:application/pdf;jama_juszczak_2019_sc_190002.pdf:/Users/neil.hawkins/Zotero/storage/Y9QUIN2W/jama_juszczak_2019_sc_190002.pdf:application/pdf;jama_wouters_2020_oi_200015 (1).pdf:/Users/neil.hawkins/Zotero/storage/2LMZEZFR/jama_wouters_2020_oi_200015 (1).pdf:application/pdf;jama_wouters_2020_oi_200015.pdf:/Users/neil.hawkins/Zotero/storage/C73L9VZ2/jama_wouters_2020_oi_200015.pdf:application/pdf;jamacardiol-2-959-s001.pdf:/Users/neil.hawkins/Zotero/storage/WI425VVY/jamacardiol-2-959-s001.pdf:application/pdf;jamadermatology_armstrong_2020_oi_190067.pdf:/Users/neil.hawkins/Zotero/storage/JCMUXNGD/jamadermatology_armstrong_2020_oi_190067.pdf:application/pdf;jamainternal_greenland_2019_vp_190001.pdf:/Users/neil.hawkins/Zotero/storage/GAUS9GMC/jamainternal_greenland_2019_vp_190001.pdf:application/pdf;jamainternal_Prasad_2017_oi_170062.pdf:/Users/neil.hawkins/Zotero/storage/C5LGHD8K/jamainternal_Prasad_2017_oi_170062.pdf:application/pdf;jamainternal_Prasad_2017_oi_170062[1730].pdf:/Users/neil.hawkins/Zotero/storage/UQDDA6MM/jamainternal_Prasad_2017_oi_170062[1730].pdf:application/pdf;jamapsychiatry_miklowitz_2020_oi_200059_1611765271.566.pdf:/Users/neil.hawkins/Zotero/storage/FTVLTT4J/jamapsychiatry_miklowitz_2020_oi_200059_1611765271.566.pdf:application/pdf;James_2009_PLATO.pdf:/Users/neil.hawkins/Zotero/storage/QCA44QIM/James_2009_PLATO.pdf:application/pdf;jbmr.3475.pdf:/Users/neil.hawkins/Zotero/storage/M5VKJP6P/jbmr.3475.pdf:application/pdf;jcm-10-01272.pdf:/Users/neil.hawkins/Zotero/storage/HWPZGF5Y/jcm-10-01272.pdf:application/pdf;jco.20.01285.pdf:/Users/neil.hawkins/Zotero/storage/ULG8TB82/jco.20.01285.pdf:application/pdf;JDV-35-1797-s001 (1).docx:/Users/neil.hawkins/Zotero/storage/GT3YBJMH/JDV-35-1797-s001 (1).docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;JDV-35-1797-s001.docx:/Users/neil.hawkins/Zotero/storage/YKEUX5W6/JDV-35-1797-s001.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;JIACRA-III-Antimicrobial-Consumption-and-Resistance-in-Bacteria-from-Humans-and-Animals.pdf:/Users/neil.hawkins/Zotero/storage/QQJE4WBD/JIACRA-III-Antimicrobial-Consumption-and-Resistance-in-Bacteria-from-Humans-and-Animals.pdf:application/pdf;Jin2019_Article_StratifiedMedicineInSchizophre.pdf:/Users/neil.hawkins/Zotero/storage/EP4TEKWC/Jin2019_Article_StratifiedMedicineInSchizophre.pdf:application/pdf;jjw167-2.pdf:/Users/neil.hawkins/Zotero/storage/5T89NBZN/jjw167-2.pdf:application/pdf;Johnson, Christensen and Kagermann (2008).pdf:/Users/neil.hawkins/Zotero/storage/2TQRWWVE/Johnson, Christensen and Kagermann (2008).pdf:application/pdf;Jones_2011_Bayesian_models_for_subgroup_analys-1.pdf:/Users/neil.hawkins/Zotero/storage/FKSIPHTE/Jones_2011_Bayesian_models_for_subgroup_analys-1.pdf:application/pdf;journal.pone.0246631.pdf:/Users/neil.hawkins/Zotero/storage/N2RIZDLR/journal.pone.0246631.pdf:application/pdf;JRSM-7-306.pdf:/Users/neil.hawkins/Zotero/storage/KFZNEFZV/JRSM-7-306.pdf:application/pdf;js.2018-00365.pdf:/Users/neil.hawkins/Zotero/storage/76R7SW3U/js.2018-00365.pdf:application/pdf;jtd-09-04-936.pdf:/Users/neil.hawkins/Zotero/storage/DLQGEFMZ/jtd-09-04-936.pdf:application/pdf;Kadane_1980.pdf:/Users/neil.hawkins/Zotero/storage/IWGKYEX9/Kadane_1980.pdf:application/pdf;Kang_2017_samp_size.pdf:/Users/neil.hawkins/Zotero/storage/IA5QN8DG/Kang_2017_samp_size.pdf:application/pdf;keaa859.pdf:/Users/neil.hawkins/Zotero/storage/6VTJCLN4/keaa859.pdf:application/pdf;keab119.pdf:/Users/neil.hawkins/Zotero/storage/LD83KM74/keab119.pdf:application/pdf;keab321.pdf:/Users/neil.hawkins/Zotero/storage/W98GAVBL/keab321.pdf:application/pdf;Keene_2014.pdf:/Users/neil.hawkins/Zotero/storage/HU82ZP5J/Keene_2014.pdf:application/pdf;kwx246.pdf:/Users/neil.hawkins/Zotero/storage/3NZHYLB4/kwx246.pdf:application/pdf;kxi047.pdf:/Users/neil.hawkins/Zotero/storage/JL9RMB7F/kxi047.pdf:application/pdf;kxx069.pdf:/Users/neil.hawkins/Zotero/storage/C5YTWHE4/kxx069.pdf:application/pdf;Learning_about_economic_evaluation_and_health_inequality.pdf:/Users/neil.hawkins/Zotero/storage/ECR5XG59/Learning_about_economic_evaluation_and_health_inequality.pdf:application/pdf;leishen.pdf:/Users/neil.hawkins/Zotero/storage/DQKQSC3H/leishen.pdf:application/pdf;Li, Chuang-Stein, Hoseyni - 2007 - The Probability of Observing Negative Subgroup Results When the Treatment Effect is Positive and Homo-annotated.pdf:/Users/neil.hawkins/Zotero/storage/V85Q3S9Y/Li, Chuang-Stein, Hoseyni - 2007 - The Probability of Observing Negative Subgroup Results When the Treatment Effect is Positive and Homo-annotated.pdf:application/pdf;Lipkovich_et_al-2017-Statistics_in_Medicine.pdf:/Users/neil.hawkins/Zotero/storage/G6XHDPSX/Lipkovich_et_al-2017-Statistics_in_Medicine.pdf:application/pdf;Liu_et_al-2017-Biometrical_Journal.pdf:/Users/neil.hawkins/Zotero/storage/A9RK8AY2/Liu_et_al-2017-Biometrical_Journal.pdf:application/pdf;Livingstone 2021.pdf:/Users/neil.hawkins/Zotero/storage/P4JIBSBW/Livingstone 2021.pdf:application/pdf;Lo2020_Article_ExploringTheBurdenOfX-linkedHy.pdf:/Users/neil.hawkins/Zotero/storage/94CLCEU4/Lo2020_Article_ExploringTheBurdenOfX-linkedHy.pdf:application/pdf;Loetal2020XLHburdenqualitativestudy.pdf:/Users/neil.hawkins/Zotero/storage/I93CFIXS/Loetal2020XLHburdenqualitativestudy.pdf:application/pdf;longpeace.pdf:/Users/neil.hawkins/Zotero/storage/36WBBRL4/longpeace.pdf:application/pdf;machine_learning_ai_in_medical_devices (1).pdf:/Users/neil.hawkins/Zotero/storage/3T4DG4AW/machine_learning_ai_in_medical_devices (1).pdf:application/pdf;MacKenzie_2015_shrinkage.pdf:/Users/neil.hawkins/Zotero/storage/G3UDIFM2/MacKenzie_2015_shrinkage.pdf:application/pdf;Mahaffey 2019 - Supplement (Inclusion-exclusion).pdf:/Users/neil.hawkins/Zotero/storage/K5MB97XV/Mahaffey 2019 - Supplement (Inclusion-exclusion).pdf:application/pdf;Mahaffey 2019 Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease.pdf:/Users/neil.hawkins/Zotero/storage/QMN5MX7A/Mahaffey 2019 Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease.pdf:application/pdf;main.pdf:/Users/neil.hawkins/Zotero/storage/XC7ZLFHM/main.pdf:application/pdf;MarginalConditional_2016_MEE.pdf:/Users/neil.hawkins/Zotero/storage/AY9W8DHK/MarginalConditional_2016_MEE.pdf:application/pdf;Mateos 2018.pdf:/Users/neil.hawkins/Zotero/storage/CZGEIYN8/Mateos 2018.pdf:application/pdf;Mateos 2019.pdf:/Users/neil.hawkins/Zotero/storage/2LGWMUYN/Mateos 2019.pdf:application/pdf;McMurray et al. 2020.pdf:/Users/neil.hawkins/Zotero/storage/AIPBNEBL/McMurray et al. 2020.pdf:application/pdf;Media_502695_smxx.pdf:/Users/neil.hawkins/Zotero/storage/U42Z63GY/Media_502695_smxx.pdf:application/pdf;medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes-pdf-51041805253.pdf:/Users/neil.hawkins/Zotero/storage/8NNWUW8K/medicines-optimisation-the-safe-and-effective-use-of-medicines-to-enable-the-best-possible-outcomes-pdf-51041805253.pdf:application/pdf;Mercer - Advanced Science Paper (002).pdf:/Users/neil.hawkins/Zotero/storage/NIVW99I4/Mercer - Advanced Science Paper (002).pdf:application/pdf;Mercer 2020.pdf:/Users/neil.hawkins/Zotero/storage/XKS37BPY/Mercer 2020.pdf:application/pdf;Methods for the analysis of multiple endpoints in small populations A review.pdf:/Users/neil.hawkins/Zotero/storage/LHTHA64Y/Methods for the analysis of multiple endpoints in small populations A review.pdf:application/pdf;methods-proposal-paper.docx:/Users/neil.hawkins/Zotero/storage/PNNW39LQ/methods-proposal-paper.docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;MFN-IFC-rule_11_20_20.pdf:/Users/neil.hawkins/Zotero/storage/EZ4JJNCT/MFN-IFC-rule_11_20_20.pdf:application/pdf;MicroRNA_Biomarkers_for_Infectious_Diseases_From_B.pdf:/Users/neil.hawkins/Zotero/storage/YG3AF9SX/MicroRNA_Biomarkers_for_Infectious_Diseases_From_B.pdf:application/pdf;Mistry_et_al-2018-Statistics_in_Medicine.pdf:/Users/neil.hawkins/Zotero/storage/6V5YIWSV/Mistry_et_al-2018-Statistics_in_Medicine.pdf:application/pdf;mmc1 (5).docx:/Users/neil.hawkins/Zotero/storage/KWWS99QA/mmc1 (5).docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;Molecularly_targeted_therapy_based_on_tumour_molec.pdf:/Users/neil.hawkins/Zotero/storage/4EAJRNBR/Molecularly_targeted_therapy_based_on_tumour_molec.pdf:application/pdf;Morris_2017.pdf:/Users/neil.hawkins/Zotero/storage/3S74PXEG/Morris_2017.pdf:application/pdf;MRC Framework for the Development Design and Analysis of Stratified Medi....pdf:/Users/neil.hawkins/Zotero/storage/TCU8LKC3/MRC Framework for the Development Design and Analysis of Stratified Medi....pdf:application/pdf;multimorbidity-clinical-assessment-and-management-pdf-1837516654789.pdf:/Users/neil.hawkins/Zotero/storage/69Z2BGEB/multimorbidity-clinical-assessment-and-management-pdf-1837516654789.pdf:application/pdf;Multinomial Paper.pdf:/Users/neil.hawkins/Zotero/storage/PMRMWV47/Multinomial Paper.pdf:application/pdf;Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf:/Users/neil.hawkins/Zotero/storage/SWVHS5QQ/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf:application/pdf;Munshi 2019 (ASH).pdf:/Users/neil.hawkins/Zotero/storage/5U3XZ5JT/Munshi 2019 (ASH).pdf:application/pdf;Munshi 2020.pdf:/Users/neil.hawkins/Zotero/storage/MVTCXSAI/Munshi 2020.pdf:application/pdf;Naci_Assessment-of-devices.pdf:/Users/neil.hawkins/Zotero/storage/MM5KMCCQ/Naci_Assessment-of-devices.pdf:application/pdf;National_Cancer_Registration_Guide-1.pdf:/Users/neil.hawkins/Zotero/storage/GXUPEBN4/National_Cancer_Registration_Guide-1.pdf:application/pdf;nature21349.pdf:/Users/neil.hawkins/Zotero/storage/ZKPFIM65/nature21349.pdf:application/pdf;nbt.1837.pdf:/Users/neil.hawkins/Zotero/storage/S7JYIYUE/nbt.1837.pdf:application/pdf;nejm_wallentin_1045sa1 (1).pdf:/Users/neil.hawkins/Zotero/storage/NZ7WXIUN/nejm_wallentin_1045sa1 (1).pdf:application/pdf;nejm_wallentin_1045sa1.pdf:/Users/neil.hawkins/Zotero/storage/L42FUJ2X/nejm_wallentin_1045sa1.pdf:application/pdf;NEJMoa0706482v1.pdf:/Users/neil.hawkins/Zotero/storage/EVKDPI5B/NEJMoa0706482v1.pdf:application/pdf;nejmoa0904327.pdf:/Users/neil.hawkins/Zotero/storage/RNGD495T/nejmoa0904327.pdf:application/pdf;nejmoa1811744_appendix.pdf:/Users/neil.hawkins/Zotero/storage/QNR8YMPH/nejmoa1811744_appendix.pdf:application/pdf;nejmoa1811744_protocol.pdf:/Users/neil.hawkins/Zotero/storage/M8R8RMEA/nejmoa1811744_protocol.pdf:application/pdf;nejmoa1914609.pdf:/Users/neil.hawkins/Zotero/storage/JBTC5LP4/nejmoa1914609.pdf:application/pdf;nejmoa2021436.pdf:/Users/neil.hawkins/Zotero/storage/ZD9GG3X2/nejmoa2021436.pdf:application/pdf;nejmoa2105215.pdf:/Users/neil.hawkins/Zotero/storage/F7TQUI8E/nejmoa2105215.pdf:application/pdf;nice-health-technology-evaluations-the-manual-pdf-72286779244741 (1).pdf:/Users/neil.hawkins/Zotero/storage/DS23DY6L/nice-health-technology-evaluations-the-manual-pdf-72286779244741 (1).pdf:application/pdf;nice-health-technology-evaluations-the-manual-pdf-72286779244741.pdf:/Users/neil.hawkins/Zotero/storage/CCMFVLKN/nice-health-technology-evaluations-the-manual-pdf-72286779244741.pdf:application/pdf;niceimpact-antimicrobial-resistance.pdf:/Users/neil.hawkins/Zotero/storage/ZKXHFYKS/niceimpact-antimicrobial-resistance.pdf:application/pdf;nihms-373252.pdf:/Users/neil.hawkins/Zotero/storage/3HQ7JBRL/nihms-373252.pdf:application/pdf;nihms-602068.pdf:/Users/neil.hawkins/Zotero/storage/HV4U3M7J/nihms-602068.pdf:application/pdf;nihms-1028423.pdf:/Users/neil.hawkins/Zotero/storage/KAV24R3T/nihms-1028423.pdf:application/pdf;nihms-1581320.pdf:/Users/neil.hawkins/Zotero/storage/APMJ9QTA/nihms-1581320.pdf:application/pdf;nihms35861.pdf:/Users/neil.hawkins/Zotero/storage/VZFTV987/nihms35861.pdf:application/pdf;nihms171933.pdf:/Users/neil.hawkins/Zotero/storage/UNM2FF8Q/nihms171933.pdf:application/pdf;nihms255748.pdf:/Users/neil.hawkins/Zotero/storage/4MVYYK5M/nihms255748.pdf:application/pdf;nihms352464.pdf:/Users/neil.hawkins/Zotero/storage/DB73TVCQ/nihms352464.pdf:application/pdf;nihms372184.pdf:/Users/neil.hawkins/Zotero/storage/3VHGHPR3/nihms372184.pdf:application/pdf;nihms418420.pdf:/Users/neil.hawkins/Zotero/storage/5V264JLN/nihms418420.pdf:application/pdf;nihms500204 (1).pdf:/Users/neil.hawkins/Zotero/storage/FVD3SIMD/nihms500204 (1).pdf:application/pdf;nihms500204.pdf:/Users/neil.hawkins/Zotero/storage/KIF2DE9D/nihms500204.pdf:application/pdf;nihms572327.pdf:/Users/neil.hawkins/Zotero/storage/BRZXSEXV/nihms572327.pdf:application/pdf;nihms591919.pdf:/Users/neil.hawkins/Zotero/storage/BWAC32ND/nihms591919.pdf:application/pdf;nihms768807.pdf:/Users/neil.hawkins/Zotero/storage/2QAK3TM6/nihms768807.pdf:application/pdf;nihms768807(1).pdf:/Users/neil.hawkins/Zotero/storage/J99WBEKC/nihms768807(1).pdf:application/pdf;NMAPaper.pdf:/Users/neil.hawkins/Zotero/storage/ITAEU2KZ/NMAPaper.pdf:application/pdf;Not_CE_at_zero_price_FINAL_14.07.14.pdf:/Users/neil.hawkins/Zotero/storage/MTLNWFVI/Not_CE_at_zero_price_FINAL_14.07.14.pdf:application/pdf;npp2015105 (1).pdf:/Users/neil.hawkins/Zotero/storage/9IBH4NNK/npp2015105 (1).pdf:application/pdf;npp2015105.pdf:/Users/neil.hawkins/Zotero/storage/NJ6XZ7S8/npp2015105.pdf:application/pdf;nrd3923.pdf:/Users/neil.hawkins/Zotero/storage/KIA2YZI6/nrd3923.pdf:application/pdf;Oakley_elicitation.pdf:/Users/neil.hawkins/Zotero/storage/YN7VUF4Q/Oakley_elicitation.pdf:application/pdf;OHE Analysis of NICE Optimised decisions - July 2020.pdf:/Users/neil.hawkins/Zotero/storage/UFCTI9UV/OHE Analysis of NICE Optimised decisions - July 2020.pdf:application/pdf;Ohlssen_2007.pdf:/Users/neil.hawkins/Zotero/storage/WPGM5EPP/Ohlssen_2007.pdf:application/pdf;Olsen2019_Article_UseOfTestAccuracyStudyDesignLa.pdf:/Users/neil.hawkins/Zotero/storage/3E4XQ3D5/Olsen2019_Article_UseOfTestAccuracyStudyDesignLa.pdf:application/pdf;Optimising Bowel Cancer Screening Phase 1 Report SCHARR 12Dec2017 (1)(1).pdf:/Users/neil.hawkins/Zotero/storage/6H2LKV68/Optimising Bowel Cancer Screening Phase 1 Report SCHARR 12Dec2017 (1)(1).pdf:application/pdf;osteoporotic-fractures-denosumab-manufacturer-submission2.pdf:/Users/neil.hawkins/Zotero/storage/JPHEICUN/osteoporotic-fractures-denosumab-manufacturer-submission2.pdf:application/pdf;Patrick Bossuyt-From Performance to Effectiveness.pdf:/Users/neil.hawkins/Zotero/storage/AE4N5PJR/Patrick Bossuyt-From Performance to Effectiveness.pdf:application/pdf;pbio.0020052.pdf:/Users/neil.hawkins/Zotero/storage/6JSAXJBR/pbio.0020052.pdf:application/pdf;PbR-Simple-Guide-FINAL.pdf:/Users/neil.hawkins/Zotero/storage/UHZDEHHW/PbR-Simple-Guide-FINAL.pdf:application/pdf;PCR_Industry_panel_response.pdf:/Users/neil.hawkins/Zotero/storage/HH33HNHL/PCR_Industry_panel_response.pdf:application/pdf;pdf.pdf:/Users/neil.hawkins/Zotero/storage/R5PUFDAK/pdf.pdf:application/pdf;PEER_stage2_10.1016_j.spl.2011.02.021.pdf:/Users/neil.hawkins/Zotero/storage/KBFE8HCD/PEER_stage2_10.1016_j.spl.2011.02.021.pdf:application/pdf;Perkovic 2019 Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.pdf:/Users/neil.hawkins/Zotero/storage/G3YRZNW7/Perkovic 2019 Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.pdf:application/pdf;PG_Case_Studies.pdf:/Users/neil.hawkins/Zotero/storage/ZPMYMJ6W/PG_Case_Studies.pdf:application/pdf;pgs-2017-0062.pdf:/Users/neil.hawkins/Zotero/storage/VRVSEF79/pgs-2017-0062.pdf:application/pdf;pharmaceutics-12-01240-v2.pdf:/Users/neil.hawkins/Zotero/storage/WCM2GD8I/pharmaceutics-12-01240-v2.pdf:application/pdf;PIIS0002914921002071.pdf:/Users/neil.hawkins/Zotero/storage/MQN633T7/PIIS0002914921002071.pdf:application/pdf;PIIS0025619619310080.pdf:/Users/neil.hawkins/Zotero/storage/USP77FKT/PIIS0025619619310080.pdf:application/pdf;PIIS109830151935140X.pdf:/Users/neil.hawkins/Zotero/storage/465A9ZRR/PIIS109830151935140X.pdf:application/pdf;PIIS0163445320305776 (1).pdf:/Users/neil.hawkins/Zotero/storage/QAW8DEZW/PIIS0163445320305776 (1).pdf:application/pdf;PIIS0167527321008287.pdf:/Users/neil.hawkins/Zotero/storage/L7LSMVW2/PIIS0167527321008287.pdf:application/pdf;PIIS0741521415022168.pdf:/Users/neil.hawkins/Zotero/storage/GLLANZ2P/PIIS0741521415022168.pdf:application/pdf;PIIS0741521419303751.pdf:/Users/neil.hawkins/Zotero/storage/INP8AMNU/PIIS0741521419303751.pdf:application/pdf;PIIS0895435609000638.pdf:/Users/neil.hawkins/Zotero/storage/F2Z9Q9SU/PIIS0895435609000638.pdf:application/pdf;PIIS0895435618310047.pdf:/Users/neil.hawkins/Zotero/storage/T8YRDEWF/PIIS0895435618310047.pdf:application/pdf;PIIS0923753419319787.pdf:/Users/neil.hawkins/Zotero/storage/VXFQFKIK/PIIS0923753419319787.pdf:application/pdf;PIIS0923753419319787(1).pdf:/Users/neil.hawkins/Zotero/storage/LUWE5FXI/PIIS0923753419319787(1).pdf:application/pdf;PIIS0923753419349865.pdf:/Users/neil.hawkins/Zotero/storage/J62UE666/PIIS0923753419349865.pdf:application/pdf;PIIS0959804921003348.pdf:/Users/neil.hawkins/Zotero/storage/2PCHUXGN/PIIS0959804921003348.pdf:application/pdf;PIIS1078588412006831.pdf:/Users/neil.hawkins/Zotero/storage/TC7MSF7V/PIIS1078588412006831.pdf:application/pdf;PIIS1098301515018471.pdf:/Users/neil.hawkins/Zotero/storage/P5RPFKVG/PIIS1098301515018471.pdf:application/pdf;PIIS1098301517319460.pdf:/Users/neil.hawkins/Zotero/storage/SJNNI8FY/PIIS1098301517319460.pdf:application/pdf;PIIS1098301518322599.pdf:/Users/neil.hawkins/Zotero/storage/87KXVGXC/PIIS1098301518322599.pdf:application/pdf;PIIS1098301519300518.pdf:/Users/neil.hawkins/Zotero/storage/IL5SS762/PIIS1098301519300518.pdf:application/pdf;PIIS1098301519300555.pdf:/Users/neil.hawkins/Zotero/storage/VYG9PK7B/PIIS1098301519300555.pdf:application/pdf;PIIS2211034818305807.pdf:/Users/neil.hawkins/Zotero/storage/ZFSDMKES/PIIS2211034818305807.pdf:application/pdf;PLATO_diabetes_ms.pdf:/Users/neil.hawkins/Zotero/storage/P3SKPHK7/PLATO_diabetes_ms.pdf:application/pdf;PLATO_Diabetes_supp_data.pdf:/Users/neil.hawkins/Zotero/storage/9LKLE5VI/PLATO_Diabetes_supp_data.pdf:application/pdf;PLATO_STEMI_ms.pdf:/Users/neil.hawkins/Zotero/storage/8YWDGFY7/PLATO_STEMI_ms.pdf:application/pdf;pme.09.49.pdf:/Users/neil.hawkins/Zotero/storage/MNRLFK3Z/pme.09.49.pdf:application/pdf;pmed.1001531 (1).pdf:/Users/neil.hawkins/Zotero/storage/FJ5VWATC/pmed.1001531 (1).pdf:application/pdf;pmed.1001531.pdf:/Users/neil.hawkins/Zotero/storage/Z398WX6W/pmed.1001531.pdf:application/pdf;pmed.1002043.pdf:/Users/neil.hawkins/Zotero/storage/PI6SCBC8/pmed.1002043.pdf:application/pdf;Pocock_2002-Statistics_in_Medicine.pdf:/Users/neil.hawkins/Zotero/storage/UGWMI6JH/Pocock_2002-Statistics_in_Medicine.pdf:application/pdf;pone.0048877.pdf:/Users/neil.hawkins/Zotero/storage/SHVB3Z4Y/pone.0048877.pdf:application/pdf;pone.0208798.pdf:/Users/neil.hawkins/Zotero/storage/APPUA2VJ/pone.0208798.pdf:application/pdf;pone.0215279 (1).pdf:/Users/neil.hawkins/Zotero/storage/NXYBU2J3/pone.0215279 (1).pdf:application/pdf;pone.0215279 (2).pdf:/Users/neil.hawkins/Zotero/storage/LUD6HBMN/pone.0215279 (2).pdf:application/pdf;pone.0215279.pdf:/Users/neil.hawkins/Zotero/storage/J6PSSDG7/pone.0215279.pdf:application/pdf;Population-adjustment-TSD-FINAL-ref-rerun.pdf:/Users/neil.hawkins/Zotero/storage/PN7LKDTJ/Population-adjustment-TSD-FINAL-ref-rerun.pdf:application/pdf;postpn_364_Drug_Pricing.pdf:/Users/neil.hawkins/Zotero/storage/D54T63TI/postpn_364_Drug_Pricing.pdf:application/pdf;presentation-exploratory-subgroup-analysis-post-hoc-subgroup-identification-clinical-trials-alex_en.pdf:/Users/neil.hawkins/Zotero/storage/9TA24PAA/presentation-exploratory-subgroup-analysis-post-hoc-subgroup-identification-clinical-trials-alex_en.pdf:application/pdf;Probability Elicitation Methods for Avoiding Biases_ An Expositio.pdf:/Users/neil.hawkins/Zotero/storage/9NTCQNLJ/Probability Elicitation Methods for Avoiding Biases_ An Expositio.pdf:application/pdf;prophly mastectomy.pdf:/Users/neil.hawkins/Zotero/storage/SCR6FEKS/prophly mastectomy.pdf:application/pdf;proportionate-universalism-can-be-our-new-normal-martyn-allison-2020.pdf:/Users/neil.hawkins/Zotero/storage/LEI7HE3Q/proportionate-universalism-can-be-our-new-normal-martyn-allison-2020.pdf:application/pdf;pst.1986 (1).pdf:/Users/neil.hawkins/Zotero/storage/HRX3PGDY/pst.1986 (1).pdf:application/pdf;pst.1986.pdf:/Users/neil.hawkins/Zotero/storage/QQ3DIX4H/pst.1986.pdf:application/pdf;radiol.11110155.pdf:/Users/neil.hawkins/Zotero/storage/VNDVIQ7M/radiol.11110155.pdf:application/pdf;radiol.2017171920.pdf:/Users/neil.hawkins/Zotero/storage/M7ZQGRVF/radiol.2017171920.pdf:application/pdf;radiol.2018182294.pdf:/Users/neil.hawkins/Zotero/storage/8E4TT3NE/radiol.2018182294.pdf:application/pdf;Ren_Oakley_Stevens_2017_Proirs.pdf:/Users/neil.hawkins/Zotero/storage/6UJWJIEQ/Ren_Oakley_Stevens_2017_Proirs.pdf:application/pdf;requirements-annex1.pdf:/Users/neil.hawkins/Zotero/storage/VCJUI8AM/requirements-annex1.pdf:application/pdf;rex.pdf:/Users/neil.hawkins/Zotero/storage/TMLDXWGL/rex.pdf:application/pdf;rmdopen-2019-001117.pdf:/Users/neil.hawkins/Zotero/storage/LIUCZ8KS/rmdopen-2019-001117.pdf:application/pdf;Rocconi-Ethington2009_Article_AssessingLongitudinalChangeAdj.pdf:/Users/neil.hawkins/Zotero/storage/GURLXJ87/Rocconi-Ethington2009_Article_AssessingLongitudinalChangeAdj.pdf:application/pdf;Rondeau2011SMMR_Curefrailty.pdf:/Users/neil.hawkins/Zotero/storage/95I3XJB6/Rondeau2011SMMR_Curefrailty.pdf:application/pdf;Rosenkranz_2016.pdf:/Users/neil.hawkins/Zotero/storage/MIG4IF79/Rosenkranz_2016.pdf:application/pdf;Rothwell - 2005 - Treating individuals 2 Subgroup analysis in randomised controlled trials Importance, indications, and interpretation-annotated.pdf:/Users/neil.hawkins/Zotero/storage/62GDSAF8/Rothwell - 2005 - Treating individuals 2 Subgroup analysis in randomised controlled trials Importance, indications, and interpretation-annotated.pdf:application/pdf;rpt_antibacterials.pdf:/Users/neil.hawkins/Zotero/storage/K34CADBS/rpt_antibacterials.pdf:application/pdf;rs140105.pdf:/Users/neil.hawkins/Zotero/storage/C9XQYP37/rs140105.pdf:application/pdf;rssa.12423.pdf:/Users/neil.hawkins/Zotero/storage/ZT7PBXN3/rssa.12423.pdf:application/pdf;s12874-015-0061-7.pdf:/Users/neil.hawkins/Zotero/storage/E5RTXGEK/s12874-015-0061-7.pdf:application/pdf;s12874-017-0327-3.pdf:/Users/neil.hawkins/Zotero/storage/2Q4TYE3Q/s12874-017-0327-3.pdf:application/pdf;s12874-017-0405-6.pdf:/Users/neil.hawkins/Zotero/storage/47PRXSHL/s12874-017-0405-6.pdf:application/pdf;s12874-019-0805-x.pdf:/Users/neil.hawkins/Zotero/storage/636MKHBW/s12874-019-0805-x.pdf:application/pdf;s12874-020-01061-4.pdf:/Users/neil.hawkins/Zotero/storage/KSANV2QZ/s12874-020-01061-4.pdf:application/pdf;s12939-015-0207-6.pdf:/Users/neil.hawkins/Zotero/storage/J7GVPVF5/s12939-015-0207-6.pdf:application/pdf;s12962-021-00290-8.pdf:/Users/neil.hawkins/Zotero/storage/56RA4GBS/s12962-021-00290-8.pdf:application/pdf;s12982-018-0083-9.pdf:/Users/neil.hawkins/Zotero/storage/RKNL7NQE/s12982-018-0083-9.pdf:application/pdf;s13023-018-0914-3.pdf:/Users/neil.hawkins/Zotero/storage/WJXAQWTF/s13023-018-0914-3.pdf:application/pdf;s13023-019-1078-5.pdf:/Users/neil.hawkins/Zotero/storage/G9SRYMY4/s13023-019-1078-5.pdf:application/pdf;s13023-020-01370-3.pdf:/Users/neil.hawkins/Zotero/storage/BEPT5MH5/s13023-020-01370-3.pdf:application/pdf;s13023-020-01666-4.pdf:/Users/neil.hawkins/Zotero/storage/SFDTYUH5/s13023-020-01666-4.pdf:application/pdf;s13063-015-0842-7 (1).pdf:/Users/neil.hawkins/Zotero/storage/PNJ53S6X/s13063-015-0842-7 (1).pdf:application/pdf;s13063-015-0842-7.pdf:/Users/neil.hawkins/Zotero/storage/FVEV68XC/s13063-015-0842-7.pdf:application/pdf;s13561-021-00327-x.pdf:/Users/neil.hawkins/Zotero/storage/BSZVVBPS/s13561-021-00327-x.pdf:application/pdf;s13643-017-0511-x.pdf:/Users/neil.hawkins/Zotero/storage/FD32R8UK/s13643-017-0511-x.pdf:application/pdf;s13643-019-1131-4.pdf:/Users/neil.hawkins/Zotero/storage/4VAJC5C7/s13643-019-1131-4.pdf:application/pdf;s13643-020-01395-6.pdf:/Users/neil.hawkins/Zotero/storage/PZWTXKAA/s13643-020-01395-6.pdf:application/pdf;s13756-020-0695-z.pdf:/Users/neil.hawkins/Zotero/storage/322T8D6X/s13756-020-0695-z.pdf:application/pdf;s40621-018-0174-7.pdf:/Users/neil.hawkins/Zotero/storage/XGI2NA3I/s40621-018-0174-7.pdf:application/pdf;s41416-019-0588-1 (1).pdf:/Users/neil.hawkins/Zotero/storage/HL8Y3VSV/s41416-019-0588-1 (1).pdf:application/pdf;s41416-019-0588-1.pdf:/Users/neil.hawkins/Zotero/storage/8KQBMV4G/s41416-019-0588-1.pdf:application/pdf;s41429-020-0300-y (1).pdf:/Users/neil.hawkins/Zotero/storage/9V93Y3Y8/s41429-020-0300-y (1).pdf:application/pdf;s41429-020-0300-y (2).pdf:/Users/neil.hawkins/Zotero/storage/F78SKHVB/s41429-020-0300-y (2).pdf:application/pdf;s41429-020-0300-y (3).pdf:/Users/neil.hawkins/Zotero/storage/AU5RCWY5/s41429-020-0300-y (3).pdf:application/pdf;s41429-020-0300-y (4).pdf:/Users/neil.hawkins/Zotero/storage/KCUDL92M/s41429-020-0300-y (4).pdf:application/pdf;s41429-020-0300-y (5).pdf:/Users/neil.hawkins/Zotero/storage/FNW9YSR6/s41429-020-0300-y (5).pdf:application/pdf;s41429-020-0300-y.pdf:/Users/neil.hawkins/Zotero/storage/G59QPI2M/s41429-020-0300-y.pdf:application/pdf;s41436-019-0730-8.pdf:/Users/neil.hawkins/Zotero/storage/W9NBMFYE/s41436-019-0730-8.pdf:application/pdf;s41467-020-20167-3.pdf:/Users/neil.hawkins/Zotero/storage/R2NN3ZRG/s41467-020-20167-3.pdf:application/pdf;s41512-019-0057-6 (1).pdf:/Users/neil.hawkins/Zotero/storage/39IYL8YD/s41512-019-0057-6 (1).pdf:application/pdf;s41512-019-0057-6.pdf:/Users/neil.hawkins/Zotero/storage/CNXGM8IT/s41512-019-0057-6.pdf:application/pdf;s41512-019-0069-2.pdf:/Users/neil.hawkins/Zotero/storage/5NEJNBZ4/s41512-019-0069-2.pdf:application/pdf;s41598-018-37092-7.pdf:/Users/neil.hawkins/Zotero/storage/PL8W6CNK/s41598-018-37092-7.pdf:application/pdf;s41598-019-47712-5.pdf:/Users/neil.hawkins/Zotero/storage/KL5T5YV9/s41598-019-47712-5.pdf:application/pdf;s41599-021-00800-2.pdf:/Users/neil.hawkins/Zotero/storage/EUV74MKZ/s41599-021-00800-2.pdf:application/pdf;s42003-021-01832-9.pdf:/Users/neil.hawkins/Zotero/storage/TTGPVQ5U/s42003-021-01832-9.pdf:application/pdf;Schnell-credsubs.pdf:/Users/neil.hawkins/Zotero/storage/8UEFG95B/Schnell-credsubs.pdf:application/pdf;Schnell-Inderst_2017_HE_BiasAdjustedEvidenceSynthesis.pdf:/Users/neil.hawkins/Zotero/storage/LHILZ2MN/Schnell-Inderst_2017_HE_BiasAdjustedEvidenceSynthesis.pdf:application/pdf;ScholteGrutters.pdf:/Users/neil.hawkins/Zotero/storage/E4QX6BRK/ScholteGrutters.pdf:application/pdf;science.aau4679.pdf:/Users/neil.hawkins/Zotero/storage/7YGFIT5N/science.aau4679.pdf:application/pdf;SECURING NEW DRUGS FOR FUTURE GENERATIONS FINAL WEB_0.pdf:/Users/neil.hawkins/Zotero/storage/MYL9QXM2/SECURING NEW DRUGS FOR FUTURE GENERATIONS FINAL WEB_0.pdf:application/pdf;Seeing_the_NICE_side_of_cost-effectiveness_analysi.pdf:/Users/neil.hawkins/Zotero/storage/M44FDYLK/Seeing_the_NICE_side_of_cost-effectiveness_analysi.pdf:application/pdf;Sequencingofdiseasemodifyingtherapiesforrelapsingremittingmultiplesclerosisatheoreticalapproachtooptimizingtreatment.pdf:/Users/neil.hawkins/Zotero/storage/FAF47PKQ/Sequencingofdiseasemodifyingtherapiesforrelapsingremittingmultiplesclerosisatheoreticalapproachtooptimizingtreatment.pdf:application/pdf;Servier ES Presentation.ppt:/Users/neil.hawkins/Zotero/storage/AARCEGWV/Servier ES Presentation.ppt:application/msword;SG.enl:/Users/neil.hawkins/Zotero/storage/83SABCIG/SG.enl:application/octet-stream;Sheiner-Beal1981_Article_SomeSuggestionsForMeasuringPre.pdf:/Users/neil.hawkins/Zotero/storage/I89Q4RYK/Sheiner-Beal1981_Article_SomeSuggestionsForMeasuringPre.pdf:application/pdf;ShrinkBayes_van de Wiel.pdf:/Users/neil.hawkins/Zotero/storage/YSEYPIY3/ShrinkBayes_van de Wiel.pdf:application/pdf;sim.2538.pdf:/Users/neil.hawkins/Zotero/storage/5RC6588W/sim.2538.pdf:application/pdf;sim.3133.pdf:/Users/neil.hawkins/Zotero/storage/4AJNZCAY/sim.3133.pdf:application/pdf;sim.4372.pdf:/Users/neil.hawkins/Zotero/storage/SVD6BYC7/sim.4372.pdf:application/pdf;sim.8086.pdf:/Users/neil.hawkins/Zotero/storage/FSTCMWD9/sim.8086.pdf:application/pdf;simstudies.zip:/Users/neil.hawkins/Zotero/storage/6NCE9TZG/simstudies.zip:application/zip;SISAQoL analysis guidelines.pdf:/Users/neil.hawkins/Zotero/storage/WSLJ9FRI/SISAQoL analysis guidelines.pdf:application/pdf;SISCERmod5_part6.pdf:/Users/neil.hawkins/Zotero/storage/RZGNQENK/SISCERmod5_part6.pdf:application/pdf;SOLVD trial.pdf:/Users/neil.hawkins/Zotero/storage/EAVZI8WW/SOLVD trial.pdf:application/pdf;SP02.pdf:/Users/neil.hawkins/Zotero/storage/GRWHDNJU/SP02.pdf:application/pdf;Spiegelhalter_2004.pdf:/Users/neil.hawkins/Zotero/storage/F87TDZM4/Spiegelhalter_2004.pdf:application/pdf;Spiegelhalter_2005_overdispersion.pdf:/Users/neil.hawkins/Zotero/storage/6VT2NC6Z/Spiegelhalter_2005_overdispersion.pdf:application/pdf;spike-slab-prior.pdf:/Users/neil.hawkins/Zotero/storage/P2KPYUIM/spike-slab-prior.pdf:application/pdf;SR0602 Crysvita - CDEC Final Recommendation May 29, 2020_For posting.pdf:/Users/neil.hawkins/Zotero/storage/FP2QDXZ3/SR0602 Crysvita - CDEC Final Recommendation May 29, 2020_For posting.pdf:application/pdf;sr0602-crysvita-pharmacoeconomic-review-report.pdf:/Users/neil.hawkins/Zotero/storage/YM3L9FXJ/sr0602-crysvita-pharmacoeconomic-review-report.pdf:application/pdf;START.xlsx:/Users/neil.hawkins/Zotero/storage/N34VGH2S/START.xlsx:application/vnd.openxmlformats-officedocument.spreadsheetml.sheet;STATA Bayes_hierarch.pdf:/Users/neil.hawkins/Zotero/storage/BC8UKSU8/STATA Bayes_hierarch.pdf:application/pdf;STATA_Sim.pdf:/Users/neil.hawkins/Zotero/storage/BKJTXCH7/STATA_Sim.pdf:application/pdf;storytelling_in_webinars_2020_final_for_sharing.pptx:/Users/neil.hawkins/Zotero/storage/BZT98MNR/storytelling_in_webinars_2020_final_for_sharing.pptx:application/vnd.openxmlformats-officedocument.presentationml.presentation;subgroup_review.pdf:/Users/neil.hawkins/Zotero/storage/SLQHYG63/subgroup_review.pdf:application/pdf;Sullivan 2020.pdf:/Users/neil.hawkins/Zotero/storage/HFRHUIMJ/Sullivan 2020.pdf:application/pdf;Sun- 2014 - Is a subgroup e ff ect believable Updating criteria to evaluate the credibility of subgroup analyses-annotated.pdf:/Users/neil.hawkins/Zotero/storage/8N3D5C8S/Sun- 2014 - Is a subgroup e ff ect believable Updating criteria to evaluate the credibility of subgroup analyses-annotated.pdf:application/pdf;suppl_material (2).docx:/Users/neil.hawkins/Zotero/storage/K87KZTQ8/suppl_material (2).docx:application/vnd.openxmlformats-officedocument.wordprocessingml.document;SupplementaryItems (1).pdf:/Users/neil.hawkins/Zotero/storage/X84C59LC/SupplementaryItems (1).pdf:application/pdf;SupplementaryItems.pdf:/Users/neil.hawkins/Zotero/storage/IUFUNYJQ/SupplementaryItems.pdf:application/pdf;t1189-nationwide-btl-product-guide (9).pdf:/Users/neil.hawkins/Zotero/storage/3DCJU847/t1189-nationwide-btl-product-guide (9).pdf:application/pdf;Tanniou_2016_1.pdf:/Users/neil.hawkins/Zotero/storage/2EUIHI3A/Tanniou_2016_1.pdf:application/pdf;Tanniou_2016.pdf:/Users/neil.hawkins/Zotero/storage/HQUGSDJV/Tanniou_2016.pdf:application/pdf;Tanniou_PhD Thesis (David McAllister's conflicted copy 2019-04-17).pdf:/Users/neil.hawkins/Zotero/storage/BG4W6G93/Tanniou_PhD Thesis (David McAllister's conflicted copy 2019-04-17).pdf:application/pdf;Tanniou_PhD Thesis.pdf:/Users/neil.hawkins/Zotero/storage/KHFBXKH3/Tanniou_PhD Thesis.pdf:application/pdf;Tecemotide START trial.pdf:/Users/neil.hawkins/Zotero/storage/BRU8JB99/Tecemotide START trial.pdf:application/pdf;Teece (2010).pdf:/Users/neil.hawkins/Zotero/storage/DY9XZMF2/Teece (2010).pdf:application/pdf;Thall_2017_mixture priors.pdf:/Users/neil.hawkins/Zotero/storage/8H7QASRG/Thall_2017_mixture priors.pdf:application/pdf;THE_HEALTH_AND_WORK_QUESTIONNAIRE_HWQ_AN_INSTRUMEN.pdf:/Users/neil.hawkins/Zotero/storage/GIFA8W4W/THE_HEALTH_AND_WORK_QUESTIONNAIRE_HWQ_AN_INSTRUMEN.pdf:application/pdf;the_personal_and_clinical_utility_of_polygenic_risk_scores.01fc4ed9.pdf:/Users/neil.hawkins/Zotero/storage/DRZN7F7C/the_personal_and_clinical_utility_of_polygenic_risk_scores.01fc4ed9.pdf:application/pdf;The_value_of_clinical_investigations_Main_revised2_no_tracks_refs_in_text_w_Figures_and_Tables.pdf:/Users/neil.hawkins/Zotero/storage/5PSFZJ4N/The_value_of_clinical_investigations_Main_revised2_no_tracks_refs_in_text_w_Figures_and_Tables.pdf:application/pdf;The-future-of-AMR-reimbursement_What-type-of-products-will-succeed.pdf:/Users/neil.hawkins/Zotero/storage/ZBEMF3VG/The-future-of-AMR-reimbursement_What-type-of-products-will-succeed.pdf:application/pdf;Thomas_2016_SG-estimation-simulation-study.pdf:/Users/neil.hawkins/Zotero/storage/VCHX2RF5/Thomas_2016_SG-estimation-simulation-study.pdf:application/pdf;Thresholds_for_statistical_and_clinical.pdf:/Users/neil.hawkins/Zotero/storage/V8FE5S96/Thresholds_for_statistical_and_clinical.pdf:application/pdf;Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization_ results from the PLATO trial..pdf:/Users/neil.hawkins/Zotero/storage/8XB258IK/Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization_ results from the PLATO trial..pdf:application/pdf;timeROC.pdf:/Users/neil.hawkins/Zotero/storage/W3C6BLXA/timeROC.pdf:application/pdf;Treatment_Switching_Guidance_Document_OCT_2016.pdf:/Users/neil.hawkins/Zotero/storage/TQDUDCD3/Treatment_Switching_Guidance_Document_OCT_2016.pdf:application/pdf;TSD1-Introduction.final_.08.05.12.pdf:/Users/neil.hawkins/Zotero/storage/VUQTYI8U/TSD1-Introduction.final_.08.05.12.pdf:application/pdf;TSD3_Heterogeneity.final_report.08.05.12.pdf:/Users/neil.hawkins/Zotero/storage/N8IUMYFM/TSD3_Heterogeneity.final_report.08.05.12.pdf:application/pdf;TSD3-Heterogeneity.final-report.08.05.12.pdf:/Users/neil.hawkins/Zotero/storage/QJALFRW5/TSD3-Heterogeneity.final-report.08.05.12.pdf:application/pdf;Tucker et al. preprint.pdf:/Users/neil.hawkins/Zotero/storage/NXXP5STS/Tucker et al. preprint.pdf:application/pdf;Tummers.pdf:/Users/neil.hawkins/Zotero/storage/FU3BRB9A/Tummers.pdf:application/pdf;Tumor-Associated_Autoantibodies_Re-Optimization_of.pdf:/Users/neil.hawkins/Zotero/storage/X96F269N/Tumor-Associated_Autoantibodies_Re-Optimization_of.pdf:application/pdf;Tx Sw in HTA Course VA KRA v1.pdf:/Users/neil.hawkins/Zotero/storage/UPTKMFIX/Tx Sw in HTA Course VA KRA v1.pdf:application/pdf;Unit_Costs_of_Health_and_Social_Care_2020 (1).pdf:/Users/neil.hawkins/Zotero/storage/3FMVJX6A/Unit_Costs_of_Health_and_Social_Care_2020 (1).pdf:application/pdf;UQ269043_OA.pdf:/Users/neil.hawkins/Zotero/storage/CGJ73U4G/UQ269043_OA.pdf:application/pdf;US Valuation of the EQ-5D Health States_Development and Testing of the D1 Valuation Model.pdf:/Users/neil.hawkins/Zotero/storage/XJW66P7S/US Valuation of the EQ-5D Health States_Development and Testing of the D1 Valuation Model.pdf:application/pdf;user-guide.pdf:/Users/neil.hawkins/Zotero/storage/DEPT2V9R/user-guide.pdf:application/pdf;VA5612_Crossover adj. mCRPC_deck_v2.0_6thJuly20.pptx:/Users/neil.hawkins/Zotero/storage/3A6YBPBQ/VA5612_Crossover adj. mCRPC_deck_v2.0_6thJuly20.pptx:application/vnd.openxmlformats-officedocument.presentationml.presentation;Value based decision making for orphan drugs with multiple criteria decision analysis burosumab for the treatment of X linked hypophosphatemia.pdf:/Users/neil.hawkins/Zotero/storage/JTJSIKDE/Value based decision making for orphan drugs with multiple criteria decision analysis burosumab for the treatment of X linked hypophosphatemia.pdf:application/pdf;value-based_strategies_for_encouraging_new_development_of_antimicrobial_drugs.pdf:/Users/neil.hawkins/Zotero/storage/YYHEVU5W/value-based_strategies_for_encouraging_new_development_of_antimicrobial_drugs.pdf:application/pdf;Varadhan_2016_BayesDS_EmpBayes.pdf:/Users/neil.hawkins/Zotero/storage/NNHFAQKG/Varadhan_2016_BayesDS_EmpBayes.pdf:application/pdf;Varewyck_2014_shrinkage.pdf:/Users/neil.hawkins/Zotero/storage/82QSQTNS/Varewyck_2014_shrinkage.pdf:application/pdf;vass_picture_1000 words.pdf:/Users/neil.hawkins/Zotero/storage/JDGGLYF4/vass_picture_1000 words.pdf:application/pdf;VBA-TA-Methods-Guide-for-Consultation.pdf:/Users/neil.hawkins/Zotero/storage/2HANLUVZ/VBA-TA-Methods-Guide-for-Consultation.pdf:application/pdf;Visible Analytics Limited - Profit and Loss.pdf:/Users/neil.hawkins/Zotero/storage/47YFFXMZ/Visible Analytics Limited - Profit and Loss.pdf:application/pdf;vollert_2020_oi_200497_1599661895.46626 (1).pdf:/Users/neil.hawkins/Zotero/storage/LGLT9V46/vollert_2020_oi_200497_1599661895.46626 (1).pdf:application/pdf;vollert_2020_oi_200497_1599661895.46626.pdf:/Users/neil.hawkins/Zotero/storage/U9XT9IR5/vollert_2020_oi_200497_1599661895.46626.pdf:application/pdf;voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf:/Users/neil.hawkins/Zotero/storage/7ZFGX8JR/voluntary-scheme-for-branded-medicines-pricing-and-access-chapters-and-glossary.pdf:application/pdf;voluntaryarbitrationframeworkforcombinationtherapies_takedawhitepaper_september2021 (1).pdf:/Users/neil.hawkins/Zotero/storage/LQCJ655U/voluntaryarbitrationframeworkforcombinationtherapies_takedawhitepaper_september2021 (1).pdf:application/pdf;Vreman2021_Article_TheApplicationAndImplicationsO.pdf:/Users/neil.hawkins/Zotero/storage/MN96LBXG/Vreman2021_Article_TheApplicationAndImplicationsO.pdf:application/pdf;Wallach_Cochrane_subgroups.pdf:/Users/neil.hawkins/Zotero/storage/KPC8N2P4/Wallach_Cochrane_subgroups.pdf:application/pdf;Wallentin_2009_PLATO NEJM.pdf:/Users/neil.hawkins/Zotero/storage/65JJ7JVE/Wallentin_2009_PLATO NEJM.pdf:application/pdf;Wang et al. - 2007 - Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials-annotated.pdf:/Users/neil.hawkins/Zotero/storage/EM82EIGJ/Wang et al. - 2007 - Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials-annotated.pdf:application/pdf;Wheeler et al. 2020.pdf:/Users/neil.hawkins/Zotero/storage/ZK67W6BT/Wheeler et al. 2020.pdf:application/pdf;When-HTA-is-confidential.pdf:/Users/neil.hawkins/Zotero/storage/TR69XCIF/When-HTA-is-confidential.pdf:application/pdf;WHO-2019-nCoV-Antigen_Detection-2020.1-eng.pdf:/Users/neil.hawkins/Zotero/storage/R7PNSFD8/WHO-2019-nCoV-Antigen_Detection-2020.1-eng.pdf:application/pdf;Wittenberg2019_Article_SpilloverEffectsOnCaregiversAn.pdf:/Users/neil.hawkins/Zotero/storage/7V7KB4H7/Wittenberg2019_Article_SpilloverEffectsOnCaregiversAn.pdf:application/pdf;Wright2019_Article_AccountingForCapacityConstrain.pdf:/Users/neil.hawkins/Zotero/storage/P3L7SHBT/Wright2019_Article_AccountingForCapacityConstrain.pdf:application/pdf;Wright2021_Article_AssessingTheQualityAndCoherenc.pdf:/Users/neil.hawkins/Zotero/storage/BIMR3USB/Wright2021_Article_AssessingTheQualityAndCoherenc.pdf:application/pdf;Wu_2008 Beta priors.pdf:/Users/neil.hawkins/Zotero/storage/6VCBB8B2/Wu_2008 Beta priors.pdf:application/pdf;ZJMA_9_1922028.pdf:/Users/neil.hawkins/Zotero/storage/UYUQUHAC/ZJMA_9_1922028.pdf:application/pdf},
}
Downloads: 0
About
Documentation
Keywords
Search
Users
Terms and Conditions of Use
Privacy Policy
Sitemap
© BibBase.org 2021